Preclinical toxicity and pharmacokinetics of a new orally bioavailable flubendazole formulation and the impact for clinical trials and risk/benefit to patients

Sophie Lachau-Durand; Lieve Lammens; Bas-jan van der Leede; Jacky Van Gompel; Graham Bailey; Marc Engelen; Ann Lampo

doi:10.1371/journal.pntd.0007026

Loading metrics

Open Access

Peer-reviewed

Research Article

Preclinical toxicity and pharmacokinetics of a new orally bioavailable flubendazole formulation and the impact for clinical trials and risk/benefit to patients

Sophie Lachau-Durand ,

Contributed equally to this work with: Sophie Lachau-Durand, Lieve Lammens

Roles Data curation, Formal analysis, Investigation, Validation, Writing – original draft, Writing – review & editing

Affiliation Drug Metabolism and Pharmacokinetics, Janssen Research & Development, A Division of Janssen Pharmaceutica NV, Beerse, Belgium
⨯
Lieve Lammens ,

Contributed equally to this work with: Sophie Lachau-Durand, Lieve Lammens

Roles Investigation, Validation, Writing – original draft, Writing – review & editing

* E-mail: llammens@its.jnj.com

Affiliation Nonclinical Safety, Janssen Research & Development, A Division of Janssen Pharmaceutica NV, Beerse, Belgium

http://orcid.org/0000-0002-7683-8745

⨯
Bas-jan van der Leede,

Roles Data curation, Formal analysis, Investigation, Methodology, Validation, Writing – review & editing

Affiliation Nonclinical Safety, Janssen Research & Development, A Division of Janssen Pharmaceutica NV, Beerse, Belgium
⨯
Jacky Van Gompel,

Roles Data curation, Formal analysis, Investigation, Validation, Writing – review & editing

Affiliation Nonclinical Safety, Janssen Research & Development, A Division of Janssen Pharmaceutica NV, Beerse, Belgium
⨯
Graham Bailey,

Roles Investigation, Validation, Writing – review & editing

Affiliation Nonclinical Safety, Janssen Research & Development, A Division of Janssen Pharmaceutica NV, Beerse, Belgium
⨯
Marc Engelen,

Roles Conceptualization, Funding acquisition, Project administration, Writing – review & editing

Affiliation Project Management Office, Janssen Research & Development, A Division of Janssen Pharmaceutica NV, Beerse, Belgium
⨯
Ann Lampo

Roles Conceptualization, Resources, Writing – review & editing

Affiliation Nonclinical Safety, Janssen Research & Development, A Division of Janssen Pharmaceutica NV, Beerse, Belgium
⨯

Preclinical toxicity and pharmacokinetics of a new orally bioavailable flubendazole formulation and the impact for clinical trials and risk/benefit to patients

Sophie Lachau-Durand,
Lieve Lammens,
Bas-jan van der Leede,
Jacky Van Gompel,
Graham Bailey,
Marc Engelen,
Ann Lampo

Published: January 16, 2019
https://doi.org/10.1371/journal.pntd.0007026

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Dogs
Is the Subject Area "Dogs" applicable to this article?

Thanks for your feedback.
Toxicity
Is the Subject Area "Toxicity" applicable to this article?

Thanks for your feedback.
Oral administration
Is the Subject Area "Oral administration" applicable to this article?

Thanks for your feedback.
Blood plasma
Is the Subject Area "Blood plasma" applicable to this article?

Thanks for your feedback.
Micronuclei
Is the Subject Area "Micronuclei" applicable to this article?

Thanks for your feedback.
Red blood cells
Is the Subject Area "Red blood cells" applicable to this article?

Thanks for your feedback.
Metabolites
Is the Subject Area "Metabolites" applicable to this article?

Thanks for your feedback.
Atrophy
Is the Subject Area "Atrophy" applicable to this article?

Thanks for your feedback.